A panel of 21 international experts are formed by the Asia-Pacific Vitreo-retina Society to work out the consensus and guidelines on polypoidal choroidal vasculopathy (PCV). PCV is a common subtype of neovascular age-related macular degeneration and is more prevalent in Asian populations. Recent advancement in imaging technology allows greater understanding of the disease process of PCV. Furthermore, non-indocyanine green angiography features in optical coherence tomography angiography have been validated for PCV diagnosis and treatment response monitoring. PCV is a subtype of nAMD characterized by the presence of polypoidal lesions and BNN that is classified as type 1 MNV. SDOCT/SSOCT can be utilized for diagnosing PCV at baseline and for monitoring its treatment response. When comprehensive assessment is required, multimodal imaging that includes ICGA should be performed.
Clinical trials provide new data on the safety and efficacy of various anti-vascular endothelial growth factor (anti-VEGF) agents as well as protocols that aim to improve the sustainability of treatments. In view of the myriads of emerging information, the panel gathered, reviewed, discussed, formulated and voted on the consensus and guidelines of PCV on four areas: 1) disease entity, 2) investigation and diagnosis, 3) treatment options, and 4) management protocol and future development in a five-point Likert scale (strongly agree, agree, neutral, disagree and strongly disagree). We proposed using a consensus score in which the maximum was 100. The summation of the respective “percentages” of experts voting for “agree” or “strongly agree” would be counted as the actual score. Consensus was achieved when the actual score of 75 or more was reached, which meant at least 75% of the experts had voted for “strongly agree” or “agree” on the consensus statement concerned.
https://www.sciencedirect.com/science/article/pii/S2162098925000118?via%3Dihub
